The Food and Drug Administration has approved the Genesys HTA System of Boston Scientific Corp. for treatment of menorrhagia, or abnormally heavy and prolonged menstrual bleeding.

The system includes a hardware and software unit that controls the procedure through tubing and a sheath of heated saline solution to the endometrial (interior) lining of the uterus.

The procedure can be done in a hospital outpatient setting under general anesthesia or a physician office using a local anesthetic.

An estimated 10 million women in the United States have menorrhagia, according to the Natick, Mass.-based vendor. More information is available at

--Joseph Goedert


Register or login for access to this item and much more

All Health Data Management content is archived after seven days.

Community members receive:
  • All recent and archived articles
  • Conference offers and updates
  • A full menu of enewsletter options
  • Web seminars, white papers, ebooks

Don't have an account? Register for Free Unlimited Access